Literature DB >> 31419417

RIBOTACs: Small Molecules Target RNA for Degradation.

Sourav K Dey1, Samie R Jaffrey2.   

Abstract

Selective RNA degradation is a powerful strategy to combat diseases or study specific RNA function. In this issue of Cell Chemical Biology, Costales et al. (2019) develop a small molecule that mediates selective RNA degradation with the potential for cancer therapeutics.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31419417     DOI: 10.1016/j.chembiol.2019.07.015

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  6 in total

1.  RIBOTACs: Small Molecules Selectively Destroy Cancer-Associated RNA.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-11-08       Impact factor: 4.345

Review 2.  Potential Therapeutics Targeting Upstream Regulators and Interactors of EHMT1/2.

Authors:  Gareth Chin Khye Ang; Amogh Gupta; Uttam Surana; Shirlyn Xue Ling Yap; Reshma Taneja
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

3.  Structure-based investigation of fluorogenic Pepper aptamer.

Authors:  Kaiyi Huang; Xianjun Chen; Chunyan Li; Qianqian Song; Huiwen Li; Linyong Zhu; Yi Yang; Aiming Ren
Journal:  Nat Chem Biol       Date:  2021-11-01       Impact factor: 15.040

4.  Identification and Verification of Molecular Subtypes with Enhanced Immune Infiltration Based on m6A Regulators in Cutaneous Melanoma.

Authors:  Yitong Lin; Shu Wang; Shirui Liu; Sha Lv; Huayang Wang; Fuqiu Li
Journal:  Biomed Res Int       Date:  2021-01-02       Impact factor: 3.411

Review 5.  Noncoding RNAs Emerging as Drugs or Drug Targets: Their Chemical Modification, Bio-Conjugation and Intracellular Regulation.

Authors:  Jin Wang; Tian Tian; Xin Li; Yan Zhang
Journal:  Molecules       Date:  2022-10-09       Impact factor: 4.927

Review 6.  The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options.

Authors:  Yating Wang; Shou-Ching Tang
Journal:  Cancer Metastasis Rev       Date:  2022-10-14       Impact factor: 9.237

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.